Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature

8 Mar 2024

Abstract excerpt

About 50% of High Grade Serous Ovarian Cancer exhibit a high degree of genomic instability due to mutation of genes involved in Homologous Recombination (HRD) and such defect accounts for synthetic lethality mechanism of PARP inhibitors (PARP-i). Several clinical trials have shown how BRCA and HRD mutational status profoundly affect first line chemotherapy as well as response to maintenance therapy with PARP-i,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38525421
DOI: 10.3389/fonc.2024.1335196

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literaturePMID 38525421Read ↗

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical ConsiderationsSemantic proximity Read ↗

Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP InhibitorsSemantic proximity Read ↗

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical PerspectivesSemantic proximity Read ↗

Unraveling Homologous Recombination Deficiency in Ovarian Cancer: A Review of Currently Available Testing PlatformsSemantic proximity Read ↗

Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnosticsSemantic proximity Read ↗

Homologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis and TreatmentSemantic proximity Read ↗

Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian CarcinomasSemantic proximity Read ↗

Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancerSemantic proximity Read ↗

PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”Semantic proximity Read ↗

Homologous recombination proficiency in ovarian and breast cancer patients.Semantic proximity Read ↗

The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?Semantic proximity Read ↗

PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage RepairSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.